NCT06639087View on ClinicalTrials.gov

A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 27, 2024

Primary Completion Date

May 29, 2025

Study Completion Date

May 29, 2025

Conditions
Renal ImpairmentHeart Failure
Interventions
DRUG

AZD5462

Participants will receive AZD5462 on top of dapagliflozin once daily.

DRUG

Dapagliflozin

Participants will receive dapagliflozin once daily with AZD5462 or placebo.

OTHER

Placebo

Participants will receive placebo on top of dapagliflozin once daily.

Trial Locations (1)

1612

Research Site, Sofia

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY